Pfizer Stock News

Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met its main goal of overall survival when tested in patients with a type of blood cancer.

Are you ready for retirement? Planning for retirement can be overwhelming, that's why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business. During a four-hour investor event last week, Pfizer pushed its initative

Pfizer's slumping revenue is a temporary hiccup considering its incredibly deep pipeline. Viatris has made important changes to its business that should pay off down the road.

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

Just because a stock's price fell does not mean it will stay down forever. Pfizer has a long roadmap for how to regain its recent glory.

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for a

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.

A financial advisor can help you understand the advantages and disadvantages of investment properties.

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

The company offers medicines and vaccines in various therapeutic areas, including: Cardiovascular metabolic and women's health under the Premarin family and Eliquis brands Biologics, small molecules,

Market sentiment is bullish but not at extreme levels, suggesting unusual developments in market sentiment, with surprisingly loose financial conditions.

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Pfizer's stock is still reeling from the decline of its coronavirus-related sales. At least one Wall Street analyst thinks that it has a bright future.

Dividend Harvesting Portfolio Week 157: $15,700 Allocated, $1,389.49 In Projected Dividends